20 years of historical data (2005–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Amicus Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $4.4B | $2.9B | $4.2B | $3.5B | $3.1B | $6.0B | $2.3B | $1.8B | $2.2B | $668M | $1.1B |
| Enterprise Value | $4.7B | $3.1B | $4.4B | $3.8B | $3.3B | $6.3B | $2.4B | $2.0B | $2.3B | $635M | $1.0B |
| P/E Ratio → | -79.83 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 8.39 | 5.43 | 10.49 | 10.72 | 10.26 | 22.91 | 12.85 | 19.51 | 59.76 | 134.73 | — |
| P/B Ratio | 22.54 | 14.78 | 26.15 | 28.68 | 10.20 | 20.87 | 4.92 | 5.19 | 6.25 | 1.85 | 3.07 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
Amicus Therapeutics, Inc.'s enterprise value stands at 139.5x EBITDA, 51% above its 5-year average of 92.7x. The Healthcare sector median is 13.8x, placing the stock at a 908% premium on an enterprise-value basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 5.86 | 10.98 | 11.64 | 10.90 | 23.98 | 13.22 | 22.16 | 62.88 | 128.16 | — |
| EV / EBITDA | 139.52 | 92.67 | — | — | — | — | — | — | — | — | — |
| EV / EBIT | 187.45 | 148.60 | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Amicus Therapeutics, Inc. earns an operating margin of 4.7%. Operating margins have expanded from -64.4% to 4.7% over the past 3 years, signaling improving operational efficiency. A negative ROE of -31.7% indicates the company is currently destroying shareholder equity. ROIC of 4.8% represents below-average returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 90.0% | 90.0% | 90.7% | 88.3% | 88.7% | 88.1% | 87.9% | 84.2% | 83.1% | 83.2% | — |
| Operating Margin | 4.7% | 4.7% | -19.3% | -64.4% | -67.6% | -94.7% | -166.8% | -360.3% | -1196.8% | -3668.6% | — |
| Net Profit Margin | -10.6% | -10.6% | -38.0% | -71.9% | -82.0% | -106.1% | -195.6% | -382.5% | -769.0% | -4034.7% | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -31.7% | -31.7% | -107.0% | -109.9% | -84.4% | -72.6% | -87.0% | -100.3% | -79.7% | -56.5% | -56.2% |
| ROA | -7.2% | -7.2% | -20.2% | -29.0% | -28.0% | -31.9% | -43.5% | -49.3% | -34.1% | -20.6% | -23.6% |
| ROIC | 4.8% | 4.8% | -14.8% | -34.3% | -29.0% | -33.4% | -40.4% | -46.8% | -83.3% | -42.1% | -45.2% |
| ROCE | 4.0% | 4.0% | -12.9% | -31.6% | -27.2% | -33.4% | -42.7% | -52.2% | -59.6% | -20.7% | -25.5% |
Solvency and debt-coverage ratios — lower is generally safer
Amicus Therapeutics, Inc. carries a Debt/EBITDA ratio of 13.3x, which is highly leveraged (327% above the sector average of 3.1x). Net debt stands at $230M ($444M total debt minus $214M cash). Interest coverage of just 0.5x is concerning — the company has limited headroom to absorb earnings volatility before struggling with debt service.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.29 | 2.29 | 2.78 | 3.67 | 1.43 | 1.54 | 0.44 | 0.94 | 0.47 | 0.43 | 0.12 |
| Debt / EBITDA | 13.27 | 13.27 | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 1.18 | 1.24 | 2.46 | 0.63 | 0.97 | 0.14 | 0.71 | 0.33 | -0.09 | -0.08 |
| Net Debt / EBITDA | 6.88 | 6.88 | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | 0.50 | 0.50 | -1.54 | -5.71 | -6.36 | -11.01 | -16.11 | -14.68 | -25.64 | -33.70 | -82.66 |
Short-term solvency ratios and asset-utilisation metrics
Amicus Therapeutics, Inc.'s current ratio of 3.39x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 2.60x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 3.05x to 3.39x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.39 | 3.39 | 2.88 | 3.05 | 4.09 | 4.47 | 4.04 | 6.40 | 5.60 | 3.06 | 2.94 |
| Quick Ratio | 2.60 | 2.60 | 2.52 | 2.88 | 3.90 | 4.32 | 3.93 | 6.30 | 5.53 | 3.03 | 2.94 |
| Cash Ratio | 1.68 | 1.68 | 1.71 | 2.11 | 3.31 | 3.73 | 3.51 | 5.85 | 5.12 | 2.98 | 2.91 |
| Asset Turnover | — | 0.67 | 0.51 | 0.45 | 0.34 | 0.29 | 0.21 | 0.12 | 0.06 | 0.00 | — |
| Inventory Turnover | 0.45 | 0.45 | 0.63 | 1.62 | 1.29 | 1.59 | 1.56 | 1.72 | 1.35 | 0.24 | — |
| Days Sales Outstanding | — | 69.85 | 80.09 | 73.39 | 62.93 | 65.65 | 66.66 | 87.85 | 93.54 | 96.00 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Amicus Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.3% | 0.0% | 0.0% | 0.0% | 0.2% | 0.1% | 0.2% | 0.2% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.3% | 0.0% | 0.0% | 0.0% | 0.2% | 0.1% | 0.2% | 0.2% |
| Shares Outstanding | — | $304M | $295M | $289M | $271M | $259M | $240M | $186M | $153M | $134M | $110M |
Compare FOLD with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| FOLDYou | $4B | -79.8 | 139.5 | — | 90.0% | 4.7% | -31.7% | 4.8% | 13.3 |
| AGIO | $2.3T | -4.2 | — | — | 88.3% | -873.9% | -30.2% | -26.6% | — |
| VRTX | $126B | 32.4 | 26.6 | 39.5 | 86.2% | 39.1% | 22.5% | 22.8% | 0.8 |
| ASND | $14B | -54.7 | — | 278.6 | 85.1% | -18.9% | — | -69.1% | — |
| BBIO | $13B | -17.5 | — | — | 94.4% | -113.3% | — | — | — |
| BMRN | $12B | 34.3 | 18.2 | 16.4 | 77.1% | 16.6% | 5.7% | 7.4% | 1.0 |
| COGT | $6B | -15.2 | — | — | — | — | -73.7% | -66.4% | — |
| PTCT | $5B | 8.8 | 5.6 | — | — | 50.1% | — | — | 0.5 |
| MIRM | $5B | -196.4 | — | 87.3 | 80.8% | -4.2% | -8.6% | -5.1% | — |
| CRNX | $4B | -8.3 | — | — | 80.1% | -9534.5% | -40.2% | -37.8% | — |
| CORT | $4B | 43.5 | 78.6 | 26.7 | 98.3% | 5.9% | 15.0% | 6.2% | 0.1 |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 20 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how FOLD stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonAmicus Therapeutics, Inc.'s current P/E ratio is -79.8x. This places it at the 50th percentile of its historical range.
Amicus Therapeutics, Inc.'s current EV/EBITDA is 139.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 92.7x.
Amicus Therapeutics, Inc.'s return on equity (ROE) is -31.7%. The historical average is -89.9%.
Based on historical data, Amicus Therapeutics, Inc. is trading at a P/E of -79.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Amicus Therapeutics, Inc. has 90.0% gross margin and 4.7% operating margin.
Amicus Therapeutics, Inc.'s Debt/EBITDA ratio is 13.3x, indicating high leverage. A ratio above 4x may signal elevated financial risk.